@Squashedhedgi @CaroleBruce17 @ABrokenBattery Oh. I see. This year before the pace trial published https://t.co/WqEHhKoPsA
@MEFoggyDog @62Sgreensill Yes they definitely did. https://t.co/6LBS0OY7ee
Like any political figure, it's interesting how much @WesselyS uses misdirection. He'll talk about XMRV but not this critique of his Cognitive Behavioural Model of ME/CFS by @keithgeraghty @davidtuller1 , Leonard Jason :) https://t.co/X4sxXFThoF
@_leftopposition @EllenGoudsmit @StenHelmfrid @SeanNeedsSleep @SMC_London It has often been said that patients who attend our service are different from those in other specialist services. We have repeatedly provided evidence this is untrue. Here’s one exa
@leestocker @BShuell @AdrianFaiers @BBCTomFeilden @BBCr4today Here is our definitive response to this claim. The patients we enter into our studies have CFS/ME whatever it is. Disagree with us by all means but please do not imply our patients do not hav
@AndrewIsaac1974 Does this at least partly reassure you? https://t.co/sh7WO63cI5
@emmajoy6 @keithgeraghty Never forgot SW & Co's XMRV paper seemingly took 3 days from receipt to accepted: https://t.co/n8IyR59GOm https://t.co/H26HKSF9dq
@MEJoBest @velogubbed AbsIolutely not. I have been seeing patients with this illness for 25 years. see http://t.co/jiLf2TWoR2
@pollyp1 Two well-cited papers whose authors chose PLOS ONE due to speed & visibility: http://t.co/ioAmxQOGTm & http://t.co/n7SlOsE9XH
PLoS ONE: Failure to Detect the Novel Retrovirus XMRV in Chronic Fatigue Syndrome http://t.co/W5tXHJZV
@ev_rat @edyong209 PLoS ONE sometimes acts in this capacity, e.g. http://t.co/yaahy3UF. We'll consider -ve results and confirmatory studies.